Ionis to hold first quarter 2024 financial results webcast
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was +1.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time
The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – info@ionisph.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – CorporateCommunications@ionisph.com – 760-603-4679
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-first-quarter-2024-financial-results-webcast-302123806.html
SOURCE Ionis Pharmaceuticals, Inc.